An Early Stage Venture Capital Investor Closes at €25 Million at Biotech Acceleration Fund

Novalis Biotech, an early-stage venture capital investor in technologies aimed at revolutionizing healthcare, announced the closing of its €25 million second fund, the Novalis Biotech Acceleration Fund. Both new and returning investors have participated in the fundraising. The second fund investor base includes institutional investors, such as Participatie Maatschappij Vlaanderen family offices, as well as HNWIs.

The Biotech Acceleration Fund will continue to invest in start-up and scale-up companies that are transforming healthcare through enabling technologies. Examples of these technologies are genomics, bioinformatics, drug research or manufacturing tools, diagnostics and personalized medicine. Investments will be split between early-stage incubation projects and later stage acceleration projects.

The investments have been made in the enabling technologies being developed by Grapheal and RheaVita. Novalis will continue leveraging its strong network in Benelux, and plans to further extend its investments across Western Europe and the U.S.Co-founder Wim Van Criekinge said that there is huge interest in the ability for innovative technology to help respond to our growing healthcare needs. They believe that enabling the technologies to identify and support early in development will meet these growing needs.

Their success from Fund 1 has been rewarded with the commitment from investors to significantly increase the size of the Biotech Acceleration Fund and provide the flexibility for larger individual investments when needed. They thank the returning and new investors for their support and shared vision. Novalis invests early and focuses on capital-light ideas, where small investments can create significant value using software, IP, tools, and other enabling technologies that can transform healthcare. Leveraging extensive networks, Novalis has a proven track record in translating innovation into successful companies.